Note: All prices and reports are based on end of the day (EOD) data.
Piramal Enterprises Limited (PEL)
What PEL does

Piramal Enterprises Limited

What company does?Diversified business including pharmaceutical, financial services, and healthcare information management.
Established1988
Entity typePrivate
HeadquartersIndia
SegmentB2B, B2C
Piramal Enterprises Limited is a share market listed company in the Non Banking Financial Company (NBFC) industry . It got listed on NSE on 08-FEB-1995 under the trading symbol PEL. On BSE it is listed under trading symbol PEL. The company operates in Pharmaceuticals , Healthcare and Finance categories.

Company overview

Piramal Enterprises Limited is a diversified global business conglomerate with operations in over 30 countries and a strong presence across various industries such as healthcare, life sciences, financial services, information management, real estate, and glass packaging. The company has garnered recognition for its innovative approach to addressing the evolving needs of customers and society at large. The company's Healthcare Insights & Analytics division provides comprehensive solutions that enable pharmaceutical companies to make informed decisions by leveraging data-driven insights. This includes advanced analytics, AI/ML models for forecasting and patient journey mapping, real-world evidence generation from medical claims data sets among others. These offerings empower clients to optimize their commercial strategies and drive better patient outcomes. In addition to this, Piramal Enterprises Limited has made significant strides in the pharmaceutical space through drug discovery research aimed at developing novel medicines targeting unmet medical needs. With a focus on innovation and cutting-edge technology platforms like Antibody Drug Conjugates (ADCs), the organization continues to push boundaries in providing transformative therapies for patients globally. One aspect that makes Piramal stand out from its competitors is its commitment towards sustainability. The company actively integrates sustainable practices throughout its value chain - be it eco-friendly manufacturing processes or promoting green initiatives within communities where it operates. Furthermore, Piramal’s strategic partnerships with leading global institutions have facilitated access to state-of-the-art technologies while fostering collaborative research efforts aimed at driving breakthrough innovations.

Overall,Piramal Enterprises Limited stands out due to its diverse portfolio spanning multiple sectors ranging from healthcare solutions using advanced analytics and drug discovery research powered by innovative technology,to an unwavering commitment towards sustainable practices along with strategic collaborations.

Disclaimer :

All prices or any other data provided here is based on previous day's closing price.

Trading or investing involves a high level of risk, including the loss of all of your investment. No information on our website should be interpreted as an investment / trading suggestion. We are not providing any kind of financial tips or recommendations. We just provide the data that you can analyse yourself and make your own decision. You are solely responsible for any of your action.

We are not SEBI registered analysts. Our website or any person associated with our website are not liable for any kind of losses, fees or charges etc.

We have tried our best to keep the data accuracy. But still we don't guarantee that our data is accurate and up to date. Verify the accuracy of data from official sources like NSE and BSE websites.

Any brand names, trademarks, or copyrighted materials used on this website are for informational purposes only. We disclaim any ownership or rights to such third-party copyrighted materials.

Stocklyzer

At stocklyzer, we provide financial tools, guides and data analysis to help you to make your decision in the financial market.

Contact us
Contact us for any kind of inquiry contact@stocklyzer.com Contact form
Stocklyzer.com © Copyright 2023. All Rights Reserved.